Catalyst
Slingshot members are tracking this event:
Paratek (PRTK) Expects Top-Line Data in Q2 2017 for Phase 3 Trial Evaluating oral Omadacycline in Treatment of Acute Bacterial Skin and Skin Structural Infections (ABSSI)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PRTK | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 03, 2017
Occurred Source:
https://slingshotinsights.com/catalysts/3437
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Abssi, Phase 3, Omadacycline
